Qiagen N.V. (QGEN) vs Bio-Techne (TECH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Bio-Techne (TECH) has outperformed Qiagen N.V. (QGEN) over the past year, gaining 22.5% versus a loss of 4.3%. Over five years, QGEN leads with a -16.0% price change compared with -41.7% for TECH. Bio-Techne is the larger company by market cap ($11.37 billion vs $9.25 billion), about 1.2 times the size, while Qiagen N.V. is growing revenue faster (+5.7% vs -0.4%).
On valuation, Qiagen N.V. trades at a lower forward P/E (17.1x vs 31.4x for Bio-Techne). Qiagen N.V. offers the higher dividend yield (0.81% vs 0.44%). Qiagen N.V. converts more of its revenue into profit, with a net margin of 20.3% versus 15.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | QGEN | TECH |
|---|---|---|
| Share price | $44.79 | $72.53 |
| Market cap | $9.25B | $11.37B |
| 1-day change | -1.88% | +0.14% |
| YTD return | -0.40% | +23.33% |
| 1-year return | -4.29% | +22.54% |
| 5-year return | -15.95% | -41.75% |
| P/E ratio (TTM) | 22.74 | 62.53 |
| Forward P/E | 17.14 | 31.36 |
| EPS (TTM) | $1.97 | $1.16 |
| Dividend yield | 0.81% | 0.44% |
| Annual dividend | $0.363 | $0.32 |
| Revenue (latest FY) | $2.09B | $1.22B |
| Revenue growth (YoY) | +5.65% | -0.38% |
| Net income (latest FY) | $424.88M | $181.86M |
| Gross margin | 62.18% | 65.77% |
| Operating margin | 22.29% | 20.73% |
| Net margin | 20.33% | 14.97% |
| 52-week high | $57.82 | $72.69 |
| 52-week low | $32.53 | $43.20 |
| Distance from 52-week high | -22.54% | -0.22% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +5.54% | -2.80% |
| Average volume | 2.76M | 3.08M |
| Shares outstanding | 206.50M | 156.82M |
| Employees | 5,500 | 3,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TECH has outperformed QGEN by 26.8 percentage points over the past year.
- Bio-Techne trades at a higher earnings multiple (62.5x vs 22.7x trailing P/E).
- Qiagen N.V. is more profitable, keeping 20.3 cents of every revenue dollar as net income versus 15.0 cents for Bio-Techne.
- Qiagen N.V. grew revenue faster in its latest fiscal year (+5.65% vs -0.38%).
About Qiagen N.V.
QGEN stock →Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5,500 employees
About Bio-Techne
TECH stock →Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 3,000 employees
QGEN vs TECH FAQ
Which is bigger, Qiagen N.V. or Bio-Techne?
Bio-Techne (TECH) is larger, with a market capitalization of $11.37B compared with $9.25B for Qiagen N.V. (QGEN).
Which stock has performed better over the past year, QGEN or TECH?
TECH returned +22.54% over the past 12 months, compared with -4.29% for QGEN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, QGEN or TECH?
QGEN has the lower trailing P/E at 22.7, versus 62.5 for TECH. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Qiagen N.V. or Bio-Techne?
Qiagen N.V. has the higher yield at 0.81%, compared with 0.44% for Bio-Techne.
Are Qiagen N.V. and Bio-Techne in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.